Articles tagged "Viral therapy"

2022 American Transplant Congress
Impact of Glecaprevir/Pibrentasvir on Tacrolimus Concentration in Solid Organ Transplant Recipients with or without Triazole Antifungal Therapy
D. Abraham¹, A. Feist², N. Law¹, S. Aslam¹, V. Nguyen¹
¹University of California San Diego Health, San Diego, CA, ²University of California San Diego, San Diego, CA
*Purpose: Provide guidance on tacrolimus (TAC) dose adjustments during glecaprevir/pibrentasvir (GLE/PIB) initiation and discontinuation in patients on triazole antifungals by comparing changes in TAC concentration-dose…
2022 American Transplant Congress
The Prevalence And Risk Factors Of De Novo Hepatitis B Virus Infection In Kidney Transplantation From Hepatitis B Antigen-positive Donors To Hbsag-negative Recipients
J. Wu¹, S. Yin¹, F. Zhang¹, L. Wu¹, X. Wang², T. Lin¹
¹urology, west china hospital, Chengdu, China, ²Urology, West China Hospital, Chengdu, China
*Purpose: To explore the prevalence and risk factors of de novo HBV infection (DNH) in kidney transplantation (KT) from HBsAg⁺ donors (D[HBsAg⁺]) to HBsAg-negative recipients…
2022 American Transplant Congress
Evaluation of the Management of Cytomegalovirus in Kidney Transplant Recipients After Establishment of a Multidisciplinary Cytomegalovirus Workgroup
A. Boyle, A. Spenningsby, H. Rhodes, T. Anderson-Haag
Hennepin County Medical Center, Minneapolis, MN
*Purpose: To assess the effectiveness of a multidisciplinary cytomegalovirus (CMV) workgroup in managing CMV in kidney transplant recipients.*Methods: Retrospective chart review at a single transplant…
2022 American Transplant Congress
Ultra-Short Duration Prophylaxis for Hepatitis C Donor Positive to Recipient Negative Simultaneous Kidney/Pancreas Transplants
G. Gupta, I. Yakubu, A. Khan, R. Sterling
Virginia Commonwealth University, Richmond, VA
*Purpose: Recent trials have successfully utilized a strategy of hepatitis C virus (HCV) D+ [Donor nucleic acid test (NAT) positive]/R- (Recipient NAT negative) kidney and/or…
2022 American Transplant Congress
Preemptive  Therapy for Cytomegalovirus (CMV) Disease Prevention in High-Risk CMV Donor Seropositive Recipient Seronegative (D+/R-) Liver Transplant Recipients in a Real-World Setting 
K. M. Doss¹, C. Kling¹, M. R. Heldman¹, N. Singh², M. Wagener³, C. E. Fisher¹, A. Limaye¹
¹University of Washington, Seattle, WA, ²University of Pittsburgh, PIttsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA
*Purpose:  Preemptive therapy  (PET)  has  demonstrated superiority to antiviral prophylaxis  for  prevention of  cytomegalovirus (CMV)  disease  in  CMV  donor seropositive/recipient seronegative (D+R-)  liver transplant recipients …
2022 American Transplant Congress
Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report
R. Saranu¹, S. Nikiforow², V. Jo³, H. So², P. Stowe², S. Tripathi¹, F. Cardarelli⁴, A. Chandraker¹
¹Renal Division, Brigham and Women's Hospital, Boston, MA, ²Dana Farber Cancer Institute, Boston, MA, ³Pathology, Brigham and Women's Hospital, Boston, MA, ⁴Allovir, Cambridge, MA
*Purpose: Epstein-Barr virus (EBV)-associated leiomyosarcomas (EBV+LMS) are neoplasms rarely seen in solid organ transplant (SOT) recipients and currently lack effective treatment options. We present a…
2022 American Transplant Congress
Impact of Dysgeusia on Transplant Recipients with Refractory Cytomegalovirus with/without Resistance Receiving Maribavir: Post-Hoc Analyses from a Phase 3 Randomized Trial
F. Silveira¹, S. Haider², D. Kaul³, O. Witzke⁴, J. Gu⁵, A. Sundberg⁵
¹Univ. Pittsburgh, Pittsburgh, PA, ²McMaster Univ., Hamilton, ON, Canada, ³Univ. Michigan, Ann Arbor, MI, ⁴Univ. Duisburg-Essen, Essen, Germany, ⁵Takeda Development Center Americas, Inc., Lexington, MA
*Purpose: In a Phase 3 study (SOLSTICE; NCT02931539), maribavir (MBV) was superior to investigator-assigned therapies (IAT; val/ganciclovir, foscarnet, or cidofovir) for CMV clearance at Wk…
2022 American Transplant Congress
Immunoglobulin M (IgM) Inhibits Replication of SARS-CoV-2 In Vero E6 Cells In Vitro and Delays Disease in K18-hACE2 Mice Infected with SARSCoV-2 In Vivo
P. Chhabra¹, B. Mann², M. Ma¹, S. Feldman³, K. L. Brayman¹
¹Department of Surgery, University of Virginia Health System, Charlottesville, VA, ²Department of Infectious Diseases, University of Virginia Health System, Charlottesville, VA, ³Center for Comparative Medicine, University of Virginia Health System, Charlottesville, VA
*Purpose: To determine if IgM has a direct effect in preventing SARS-CoV-2 replication in Vero E6 cells, and delaying or preventing disease in infected K18-hACE2…
2022 American Transplant Congress
Adenosine A2A Receptor (A2AR) Agonist Apadenoson Promotes Survival in K28-hACE2 Mice and Syrian Hamsters Infected with Sars-CoV-2
P. Chhabra¹, B. Mann², M. Ma¹, S. Feldman³, J. Linden⁴, K. L. Brayman¹
¹Department of Surgery, University of Virginia Health System, Charlottesville, VA, ²Department of Infectious Diseases, University of Virginia Health System, Charlottesville, VA, ³Center for Comparative Medicine, University of Virginia Health System, Charlottesville, VA, ⁴Department of Nephrology, University of Virginia Health System, Charlottesville, VA
*Purpose: To determine if Apadenoson or Regadenoson has a therapeutic effect in attenuating hyper-inflammation and improving survival rate in K18-hACE2mice or Syrian hamsters infected with…
2022 American Transplant Congress
Metagenomic Next-Generation Sequencing Reveals the Profile of Viral Infections in Kidney Transplant Recipients During the Covid-19 Pandemic
X. Tian, W. Duan, C. Zhang, X. Wu, T. Yan
Henan Province People's Hospital, Zhengzhou, Henan Province, China
*Purpose: To study the clinical application of metagenomic next-generation sequencing (mNGS) in the detection of viral infections in kidney transplant recipients (KTRs) during the COVID-19…